University of California, U. Vienna, Charpentier Awarded Fourth U.S. CRISPR-Cas9 Patent

Genetic Engineering & Biotechnology News reports, “A fourth U.S. patent covering CRISPR-Cas9 claims was granted today to the Regents of the University of California (UC), the University of Vienna, and CRISPR pioneer Emmanuelle Charpentier, PhD, director and scientific member at the Max Planck Institute of Infection Biology, Berlin. U.S. Patent No. 10,266,850, ‘Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription,’ focuses on systems and methods for using CRISPR/Cas9 technology in a single guide format, including uses to target and edit or modulate genes.”

Referencing client The University of California, Berkeley, Director Eldora L. Ellison, Ph.D. is quoted in the coverage, “We are very pleased at the progress we’re making with the issuance of this patent and will continue to promote the intellectual property of the Doudna-Charpentier team’s CRISPR-Cas9 invention. Today’s patent further builds on the numerous CRISPR-Cas9 applications in UC’s portfolio and will support the university’s commitment to utilizing the genome editing technology for the benefit of our society.”